Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Leptin Resistance Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LEPROT (Leptin Receptor Overlapping Transcript) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LEPROT ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed for native glycosylation. |
View LEPROT Products |
| Gene Delivery | LEPROT Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Critical for trafficking and surface expression assays. |
View LEPROT Products |
| Benchmark Ab | Anti-LEPROT Monoclonal Antibody Recombinant positive control for Western blot, flow cytometry, and IHC validation. |
View LEPROT Products |
| Validator | LEPROT siRNA Set (3 unique sequences) For knockdown verification and specificity controls in functional assays. |
View LEPROT Products |
| Related Target: LEPR | Leptin Receptor (LEPR) Primary receptor regulated by LEPROT. Essential for co-expression and interaction studies. |
View LEPR Products |
| Related Target: LEP | Leptin (LEP) Endogenous ligand for LEPR. Functional control for obesity/metabolic pathway studies. |
View LEP Products |
| Related Target: MC4R | Melanocortin 4 Receptor Downstream effector in leptin signaling pathway. Synergistic target for combination therapy. |
View MC4R Products |
| Related Target: GHR | Growth Hormone Receptor (GHR) Also regulated by LEPROT; important for cross-reactivity profiling and indication expansion. |
View GHR Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Surface Trafficking Quantification | Full-length LEPROT Lentivirus with C-terminal V5 tag. Sequence Verified. Enables quantitative flow cytometry of ER-to-membrane transport. |
| Cross-species Cyno/Mouse/Human evaluation | Ortholog protein panel (Human/Mouse/Cyno) available with >95% purity. Species-specific ECD domains verified by mass spectrometry. |
| Lack of Specificity Controls | Validated siRNA set and CRISPR-resistant ORF rescue constructs included for genetic validation. |
| Interaction with LEPR | Co-expression lentivirus systems available. High-avidity ECD-Fc constructs for pull-down assays. |
Live LEPROT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The metabolic disease field is experiencing a paradigm shift with the success of incretin-based therapies, yet leptin resistance remains a critical unmet need in obesity management. LEPROT, as the critical chaperone regulating LEPR surface expression, represents a novel upstream intervention point. Rather than flooding the system with leptin analogs, next-generation therapeutics targeting LEPROT aim to restore endogenous receptor trafficking and sensitivity. The race is intensifying to develop small molecule chaperone enhancers, RNAi/ASO modalities, and biologics that modulate LEPROT function, with major players pivoting toward combination strategies that address both leptin sensitivity and melanocortin pathway activation. First-generation therapies are approaching the clinic, and the next wave is targeting synergistic combinations with GLP-1 receptor agonists to overcome weight-loss plateaus.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Chaperone Modulators (Small Molecule) | Novo Nordisk, Eli Lilly, Academic Consortia | Leptin-resistant Obesity, Metabolic Syndrome | Surface Expression Assay (Need full-length LEPROT lentivirus for trafficking quantification) |
| Biologics (mAbs) | Amgen, Pfizer | Lipodystrophy, Severe Obesity | Internalization/Recycling Assays (Need high-purity ECD-Fc for FACS-based binding studies) |
| Gene Therapy & Editing | Regeneron, Novartis, Academic Consortia | Congenital Leptin Receptor Deficiency, Severe Genetic Obesity | Stable Cell Line Construction & Functional Screening (Need high-titer lentivirus for long-term expression) |
| Peptide Conjugates | Rhythm Pharmaceuticals | MC4R-related Obesity (Combination) | Pathway Crosstalk Studies (Need LEPROT + MC4R co-expression systems) |
| RNAi / ASO | Metabolic Innovators | Metabolic Syndrome | Knockdown Validation (Need validated siRNA set and lentivirus-based stable lines) |